February 2021 Volume 17, Issue 2
Volume 17, Issue 2 | February 2021
February 2021
In this Issue
Discovery
Rekindling an Old Flame: Targeting tumors with bacteria
Bacteria have proven to be essential partners in everyday life, but can they also treat cancer?Could Siglec-12 cause cancers to advance?
People who produce this protein may be at twice the risk for advanced cancer
Scientists map structure of potent antibody against coronavirus
Computer-generated images show why immune protein neutralizes SARS-CoV-2InveniAI and Kyowa Kirin partner on target discovery
The companies have expanded an existing collaboration to find novel targets
Preclinical
Introducing NGM438
NGM438 is an antagonist antibody that inhibits LAIR1
Talking about a resolution
Data show that OSE-230 can resolve chronic inflammation
HCA with 3D models
InSphero-Yokogawa partnership will support drug development researchOut with the old, in with the new
New cancer immunotherapy shows promise in treating cancerClinical Trials
Extending a new option with ExteNET
Puma reports that neratinib improved CNS outcomes in HER2-positive breast cancer patients
Ibrexafungerp advances the fight against fungus
IV compound enters Phase 1, following FDA Priority Review and Fast Track designations for oral formulationIntratumoral therapy
Plasmid DNA delivery platform looks promising for metastatic melanoma therapy
Chimerix acquires Oncoceutics
Move will expand Chimerix pipeline with late-stage oncology programDiagnostics
AI is put to work on NASH biomarkers
iBiopsy study shows promise in diagnosing severity of disease in patients
Ingestible capsule offers in-depth diagnostics
Progenity presents results on PIL Dx capsule in small intestinal bacterial overgrowthTools & Technology
Drug dissolution solution
Researchers develop method of assessing time-release drugsA cHAT about chemistry
Rice University chemists detail a greener way to make pharmaceutical intermediatesA helping hand from Hemibody
MorphoSys licenses Hemibody technology from Cherry Biolabs in hopes of improving T cell-based therapeuticsSpecial Reports
Special Report on Natural Products: Mining metabolites
Rebirth of an industry requires reinventionEditor's Focus
Infectious disease research is a triathlon
Dealing with viruses, bacteria and other pathogens requires many approachesA great leap from clinical trials to clinical practice
There is potential for better tying clinical practice to clinical trials, but when will we get there?Feature
Focus Feature on Vaccines
mRNA approaches vs. SARS-CoV-2, plus more news of infectious disease and cancer vaccinesCommentary
